^
Association details:
| Biomarker: | NRG1 mutation |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | erlotinib (EGFR inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Excerpt:
Both afatinib and erlotinib plus pertuzumab resulted in clinically relevant responses in patients with NRG1-rearranged PDAC identified in this study.
DOI:
10.1158/2159-8290.CD-18-0036
